A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administered HRS9531
Latest Information Update: 01 Nov 2023
At a glance
- Drugs HRS 9531 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Fujian Shengdi Pharmaceutical
- 06 Oct 2023 Results assessing Safety, tolerability, pharmacokinetics , and pharmacodynamics of HRS9531 in healthy subjects presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 26 Jun 2023 Results assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 in Healthy Subjects presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.